A single case of a 13-year-old male with biallelic RPE65-IRD who received bilateral voretigene neparvovec (VN) without subretinal foveal detachment, followed for approximately 4 years to assess long-term visual and structural outcomes.
Initial BCVA improved by 3–4 lines (to 0.20–0.30 logMAR) and FST improved up to -39.1 dB at 6 weeks; by ~4 years, BCVA had declined markedly (0.68–0.90 logMAR) and FST worsened to -18.2 to -22.8 dB, with OCT showing foveal outer retinal atrophy and chorioretinal atrophy (CRA) along the vascular arcade.
Single case report with no comparator; causality between VN treatment (vs. natural disease progression) and CRA cannot be established; immunosuppression protocol details are not fully described.
Patients treated with voretigene neparvovec should be monitored long-term, as delayed foveal atrophy can emerge years after initial visual gains. Those with large early FST improvements may warrant modified or extended immunosuppression to reduce CRA risk.
Explore related topics